AlphaFold predicted structure
CALM3 · P0DP25

Mean pLDDT
85.5/ 100
Confident
149 residues
Confidence breakdown
- Very high(≥ 90)46%
- Confident(70–90)44%
- Low(50–70)8%
- Very low(< 50)2%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
calmodulin 3
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
Catecholaminergic polymorphic VT
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownLong QT syndrome
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownShort QT syndrome
long QT syndrome 16
long QT syndrome 1
bacterial infectious disease
Prolonged QT interval
familial long QT syndrome
neurodegenerative disease
Romano-Ward syndrome
catecholaminergic polymorphic ventricular tachycardia
Abnormality of the cardiovascular system
atrial fibrillation
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Calmodulin-3
Calmodulin acts as part of a calcium signal transduction pathway by mediating the control of a large number of enzymes, ion channels, aquaporins and other proteins through calcium-binding (PubMed:16760425, PubMed:31454269). Calcium-binding is required for the activation of calmodulin (PubMed:16760425, PubMed:31454269, PubMed:35568036). Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain kinases and calmodulin-dependent protein kinase type II (CaMK2), and phosphatases (PubMed:16760425, PubMed:35568036). Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis (PubMed:16760425)
CALM3 · P0DP25

Mean pLDDT
85.5/ 100
Confident
149 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0